ArticleBMC microbiology2026
Repurposing lusutrombopag: unveiling anti-Staphylococcus aureus activity in a novel oral thrombopoietin receptor agonist.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evolving Patterns of TPO-RA Use in Children: A Decade of Single-Centre Experience and Narrative Review.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundStaphylococcus aureus (S. aureus), designated by the World Health Organization (2024) as a high-priority pathogen for hospital-acquired infections, necessitates innovative therapeutics. Drug repurposing has emerged as a pivotal strategy for antimicrobial discovery.
objectiveTo assess the antibacterial efficacy of Lusutrombopag (Lbg) against S. aureus and characterize its mechanism of action.
resultsHerein, we discovered Lbg, an FDA-approved thrombopoietin receptor agonist clinically used for thrombocytopenia, as a potent anti-staphylococcal agent. Lbg exhibited activity against methicillin-susceptible and -resistant S. aureus (MSSA/MRSA) clinical isolates, with MIC values of 6.25 ~ 25 µM. Notably, it indicated synergy in combination with erythromycin (FICI = 0.5) and gentamicin (FICI = 0.25) against S. aureus SA113. Proteomic analysis confirmed the downregulation of key virulence factors, such as HrtA, HrtB, and Hly. These findings were further supported by qRT-PCR, which showed corresponding reductions in the transcription levels of these genes. Subsequent in vitro experiments validated the functional impact of these molecular changes: at sub-MIC concentrations, Lbg inhibited biofilm formation and attenuated virulence by suppressing hemolytic activity and staphyloxanthin biosynthesis. Mechanistic studies via Drug Affinity Responsive Target Stability (DARTS) assays indicated ribosomal targeting, with 17 of 44 upregulated proteins being ribosome-related proteins, corresponding to genes such as rplD, rpsR, rpsC and rpsZ. This suggests that Lbg may impair bacterial protein translation, potentially leading to alterations in membrane potential/permeability and a consequent reduction in virulence. Lbg enhanced survival in Galleria mellonella (G. mellonella) infection models and reduced bacterial load in murine pulmonary infection models.
conclusionsCollectively, the dual pharmacological profile of repurposed Lbg, providing both hematological support and direct antimicrobial effects, indicates its potential as a therapeutic approach for MRSA infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.